CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
[¹⁴C]-LY3202626drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02555449
NCT02555449Phase 1Completed
CompareCT.gov

Disposition of [¹⁴C]-LY3202626 Following Oral Administration in Healthy Male Subjects

Eli Lilly and Company·interventional·Posted Sep 21, 2015·Updated Apr 19, 2021

In Brief

A Phase 1 clinical trial evaluating [¹⁴C]-LY3202626 for Healthy. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to measure how much of the specially prepared study drug, LY3202626, containing radiolabeled carbon \[¹⁴C\] gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. Participants will stay at a clinical research unit (CRU). The study will last about 28 days (check in to follow-up) for each participant. This study is for research purposes only and is not intended to treat any medical condition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 21, 2015
Enrollment StartSep 1, 2015
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.8 years ago

Interventions

[¹⁴C]-LY3202626drug

Administered as solution by mouth